Regenerative Medicine Insights

This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.

This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.